Abstract
BackgroundRecently, the US Food and Drug Administration (FDA) has approved immune checkpoint blockade (ICB) for treating cancer patients with tumor mutation burden (TMB) >10 mutations/megabase (mut/Mb). However, high TMB (TMB-H)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have